BR0311932A - Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado - Google Patents
Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinadoInfo
- Publication number
- BR0311932A BR0311932A BR0311932-7A BR0311932A BR0311932A BR 0311932 A BR0311932 A BR 0311932A BR 0311932 A BR0311932 A BR 0311932A BR 0311932 A BR0311932 A BR 0311932A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- insulin resistance
- treating
- pharmaceutical formulation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000002361 compost Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201935A SE0201935D0 (sv) | 2002-06-20 | 2002-06-20 | Therapeutic agents |
| SE0203826A SE0203826D0 (sv) | 2002-12-20 | 2002-12-20 | Therapeutic agents |
| PCT/GB2003/002584 WO2004000790A1 (en) | 2002-06-20 | 2003-06-17 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311932A true BR0311932A (pt) | 2005-03-22 |
Family
ID=30002442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311932-7A BR0311932A (pt) | 2002-06-20 | 2003-06-17 | Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7355069B2 (https=) |
| EP (1) | EP1517883B8 (https=) |
| JP (2) | JP3782818B2 (https=) |
| KR (1) | KR20050014013A (https=) |
| CN (1) | CN1319938C (https=) |
| AR (1) | AR039713A1 (https=) |
| AT (1) | ATE386013T1 (https=) |
| AU (1) | AU2003240099B2 (https=) |
| BR (1) | BR0311932A (https=) |
| CA (1) | CA2489834C (https=) |
| DE (1) | DE60319084T2 (https=) |
| DK (1) | DK1517883T3 (https=) |
| ES (1) | ES2299702T3 (https=) |
| IL (1) | IL165671A0 (https=) |
| IS (1) | IS7627A (https=) |
| MX (1) | MXPA04012686A (https=) |
| NO (1) | NO20045353L (https=) |
| PL (1) | PL375074A1 (https=) |
| PT (1) | PT1517883E (https=) |
| RU (1) | RU2004137094A (https=) |
| TW (1) | TWI282784B (https=) |
| WO (1) | WO2004000790A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| FR2875805B1 (fr) * | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
| GB0522433D0 (en) * | 2005-11-03 | 2005-12-14 | Astrazeneca Ab | Therapeutic agents |
| GB0522431D0 (en) * | 2005-11-03 | 2005-12-14 | Astrazeneca Ab | Chemical process |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK148576A (da) | 1975-04-18 | 1976-10-19 | Boehringer Mannheim Gmbh | Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling |
| DE19615263A1 (de) | 1996-04-18 | 1997-10-23 | Bayer Ag | Benzyloxy-substituierte Phenylglycinolamide |
| BR9814087A (pt) | 1997-10-17 | 2000-10-03 | Aventis Pharm Prod Inc | Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente |
| EP1040108B1 (en) | 1997-12-19 | 2004-02-25 | Schering Aktiengesellschaft | Ortho-anthranilamide derivatives as anti-coagulants |
| SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| GB9822473D0 (en) | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| NZ515086A (en) | 1999-04-28 | 2003-10-31 | Aventis Pharma Gmbh | Di-aryl acid derivatives as PPAR receptor ligands |
| EP1177176B1 (en) | 1999-04-28 | 2006-04-19 | Aventis Pharma Deutschland GmbH | Tri-aryl acid derivatives as ppar receptor ligands |
| JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| US6509374B2 (en) | 2000-04-17 | 2003-01-21 | Novo Nordisk A/S | Compounds, their preparation and use |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0116955D0 (en) | 2001-07-11 | 2001-09-05 | Syngenta Ltd | Weed control process |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| TWI331143B (en) | 2001-09-08 | 2010-10-01 | Astrazeneca Uk Ltd | Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| US7351858B2 (en) | 2002-06-20 | 2008-04-01 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| SE0201936D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| SE0201937D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| GB0314130D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314131D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314075D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314078D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314260D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2003
- 2003-06-17 PL PL03375074A patent/PL375074A1/xx not_active Application Discontinuation
- 2003-06-17 JP JP2004515007A patent/JP3782818B2/ja not_active Expired - Lifetime
- 2003-06-17 CN CNB038194740A patent/CN1319938C/zh not_active Expired - Fee Related
- 2003-06-17 KR KR10-2004-7020670A patent/KR20050014013A/ko not_active Withdrawn
- 2003-06-17 CA CA002489834A patent/CA2489834C/en not_active Expired - Fee Related
- 2003-06-17 BR BR0311932-7A patent/BR0311932A/pt not_active IP Right Cessation
- 2003-06-17 DE DE60319084T patent/DE60319084T2/de not_active Expired - Lifetime
- 2003-06-17 TW TW092116378A patent/TWI282784B/zh not_active IP Right Cessation
- 2003-06-17 US US10/518,007 patent/US7355069B2/en not_active Expired - Fee Related
- 2003-06-17 MX MXPA04012686A patent/MXPA04012686A/es not_active Application Discontinuation
- 2003-06-17 EP EP03732713A patent/EP1517883B8/en not_active Expired - Lifetime
- 2003-06-17 ES ES03732713T patent/ES2299702T3/es not_active Expired - Lifetime
- 2003-06-17 WO PCT/GB2003/002584 patent/WO2004000790A1/en not_active Ceased
- 2003-06-17 RU RU2004137094/04A patent/RU2004137094A/ru not_active Application Discontinuation
- 2003-06-17 AT AT03732713T patent/ATE386013T1/de not_active IP Right Cessation
- 2003-06-17 AU AU2003240099A patent/AU2003240099B2/en not_active Ceased
- 2003-06-17 DK DK03732713T patent/DK1517883T3/da active
- 2003-06-17 PT PT03732713T patent/PT1517883E/pt unknown
- 2003-06-20 AR ARP030102197A patent/AR039713A1/es not_active Application Discontinuation
-
2004
- 2004-12-07 NO NO20045353A patent/NO20045353L/no not_active Application Discontinuation
- 2004-12-09 IL IL16567104A patent/IL165671A0/xx unknown
-
2005
- 2005-01-05 IS IS7627A patent/IS7627A/is unknown
-
2006
- 2006-01-27 JP JP2006019068A patent/JP2006182782A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20050256198A1 (en) | 2005-11-17 |
| AU2003240099A1 (en) | 2004-01-06 |
| RU2004137094A (ru) | 2005-08-10 |
| ATE386013T1 (de) | 2008-03-15 |
| TWI282784B (en) | 2007-06-21 |
| IS7627A (is) | 2005-01-05 |
| DK1517883T3 (da) | 2008-05-26 |
| MXPA04012686A (es) | 2005-03-23 |
| DE60319084D1 (de) | 2008-03-27 |
| CA2489834C (en) | 2006-10-03 |
| CA2489834A1 (en) | 2003-12-31 |
| DE60319084T2 (de) | 2009-01-29 |
| PL375074A1 (en) | 2005-11-14 |
| TW200409747A (en) | 2004-06-16 |
| US7355069B2 (en) | 2008-04-08 |
| HK1073838A1 (en) | 2005-10-21 |
| EP1517883A1 (en) | 2005-03-30 |
| CN1675171A (zh) | 2005-09-28 |
| ES2299702T3 (es) | 2008-06-01 |
| AR039713A1 (es) | 2005-03-09 |
| JP3782818B2 (ja) | 2006-06-07 |
| AU2003240099B2 (en) | 2007-02-01 |
| EP1517883B1 (en) | 2008-02-13 |
| PT1517883E (pt) | 2008-04-21 |
| IL165671A0 (en) | 2006-01-15 |
| JP2006182782A (ja) | 2006-07-13 |
| NO20045353L (no) | 2005-01-20 |
| KR20050014013A (ko) | 2005-02-05 |
| JP2005529970A (ja) | 2005-10-06 |
| EP1517883B8 (en) | 2008-05-21 |
| WO2004000790A1 (en) | 2003-12-31 |
| CN1319938C (zh) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214986A (pt) | S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BR0113039A (pt) | Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto | |
| BRPI0415746A (pt) | derivados de amida | |
| BRPI0110955B8 (pt) | derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos. | |
| BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR0308816A (pt) | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas | |
| BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
| BRPI0201437B8 (pt) | processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos | |
| BRPI0415437A (pt) | composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto | |
| BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| BR0308056A (pt) | Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BR0309012A (pt) | Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto | |
| NO20051263L (no) | Ny anvendelse av benzotiazolderivater | |
| NO20071109L (no) | Indol-2-karboksamidinderivater som NMDA-reseptorantagonister | |
| BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
| BR0016133A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| BR0317680A (pt) | Composto, composição farmacêutica, uso de um composto, ou de um sal farmaceuticamente aceitável do mesmo, método de tratamento de um ser humano, e, processo para a preparação de um composto | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| BR0016130A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| BRPI0414780A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia da dor em um animal de sangue quente, e para preparar um composto | |
| NO20045222L (no) | Benzosyrederivater som modulatorer av PPAR alfa og gamma | |
| BR0308765A (pt) | Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7 | |
| BR0211171A (pt) | Compostos quìmicos | |
| BR0315995A (pt) | Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |